{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:05:58Z","timestamp":1788393958073,"version":"build-2803163510"},"reference-count":55,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2024,11,1]]},"abstract":"\n Importance<\/jats:title>\n The correlation between serum levels of autoantibodies against bullous pemphigoid (BP) antigens 180 (BP180) and 230 (BP230) with BP disease severity is unclear.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To investigate the correlation of anti-BP180 and anti-BP230 immunoglobulin G (IgG) antibody levels with BP disease severity.<\/jats:p>\n <\/jats:sec>\n \n Data Sources<\/jats:title>\n A search was performed of the Cochrane Central Register of Controlled Trials, Embase, and PubMed databases from their respective inception to April 11, 2024.<\/jats:p>\n <\/jats:sec>\n \n Study Selection<\/jats:title>\n Studies evaluating the correlation between serum levels of anti-BP180 or anti-BP230 IgG measured using enzyme-linked immunosorbent assay (ELISA) and disease severity assessed per the Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) or BP Disease Area Index (BPDAI) were included. No language or geographic restrictions were imposed. Nearly 0.4% of initially identified studies met the selection criteria.<\/jats:p>\n <\/jats:sec>\n \n Data Extraction and Synthesis<\/jats:title>\n One researcher extracted data and another researcher confirmed data. The risk of bias was independently assessed by these researchers using the Quality Assessment of Diagnostic Accuracy Studies 2 tool, with discrepancies resolved by discussion with a third researcher. A random-effects model meta-analysis and a subgroup analysis were conducted based on the ELISA kit manufacturers.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Pooled correlation coefficients of antibody levels with ABSIS and BPDAI.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n In all, 14 studies with 1226 participants were analyzed. The risk of bias of included studies was generally low. The meta-analysis found anti-BP180 autoantibody levels showed moderate correlation with objective BPDAI (\n r =<\/jats:italic>\n 0.56; 95% CI, 0.46-0.64) at baseline, strong correlation (\n r =<\/jats:italic>\n 0.63; 95% CI, 0.39-0.79) at 3-month follow-up, and moderate correlation (\n r =<\/jats:italic>\n 0.53; 95% CI, 0.25-0.72) at 6-month follow-up. Anti-BP180 autoantibody levels also showed moderate correlation (\n r =<\/jats:italic>\n 0.52; 95% CI, 0.39-0.62) with ABSIS at baseline, strong correlation (\n r =<\/jats:italic>\n 0.62; 95% CI, 0.39-0.79) at 3-month follow-up, and moderate correlation (\n r =<\/jats:italic>\n 0.53; 95% CI, 0.25-0.72) at 6-month follow-up. By contrast, anti-BP230 autoantibody levels showed no association with objective BPDAI and ABSIS at diagnosis and follow-up. The subgroup analysis found similar results when using different ELISA kits.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n The findings of this systematic review and meta-analysis indicated that anti-BP180 autoantibody levels may serve as an adjunctive tool for monitoring BP disease severity and guiding clinical care for patients with BP.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamadermatol.2024.3425","type":"journal-article","created":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T11:36:22Z","timestamp":1727868982000},"page":"1192","source":"Crossref","is-referenced-by-count":28,"title":["Bullous Pemphigoid Severity and Levels of Antibodies to BP180 and BP230"],"prefix":"10.1001","volume":"160","author":[{"given":"Po-Yi","family":"Chou","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Chang Gung Memorial Hospital, Linkou Main Branch, Taoyuan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Ling","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Chang Gung Memorial Hospital, Linkou Main Branch, Taoyuan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiao-Ni","family":"Wen","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Chang Gung Memorial Hospital, Linkou Main Branch, Taoyuan, Taiwan"},{"name":"Department of Medical Biotechnology and Laboratory Science, Chang Gung University, Taoyuan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Kang","family":"Tu","sequence":"additional","affiliation":[{"name":"Institute of Health Data Analytics and Statistics, College of Public Health, National Taiwan University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Chi","family":"Chi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Chang Gung Memorial Hospital, Linkou Main Branch, Taoyuan, Taiwan"},{"name":"School of Medicine, College of Medicine, Chang Gung University, Taoyuan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"10","key":"doi240039r1","doi-asserted-by":"publisher","first-page":"4818","DOI":"10.1111\/jocd.14797","article-title":"Global incidence and prevalence of bullous pemphigoid: a systematic review and meta-analysis.","volume":"21","author":"Lu","year":"2022","journal-title":"J Cosmet Dermatol"},{"issue":"4","key":"doi240039r2","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.jaci.2020.02.013","article-title":"Autoimmune bullous skin diseases, pemphigus and pemphigoid.","volume":"145","author":"Egami","year":"2020","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"doi240039r3","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1111\/bjd.20743","article-title":"The global incidence of bullous pemphigoid: a systematic review and meta-analysis.","volume":"186","author":"Persson","year":"2022","journal-title":"Br J Dermatol"},{"issue":"10","key":"doi240039r4","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.3390\/medicina57101061","article-title":"Bullous Pemphigoid and Other Pemphigoid Dermatoses.","volume":"57","author":"Pratasava","year":"2021","journal-title":"Medicina (Kaunas)"},{"key":"doi240039r5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.912876","article-title":"Insights into the pathogenesis of bullous pemphigoid: the role of complement-independent mechanisms.","volume":"13","author":"Cole","year":"2022","journal-title":"Front Immunol"},{"key":"doi240039r6","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.3389\/fimmu.2019.01506","article-title":"New insights into the pathogenesis of bullous pemphigoid: 2019 update.","volume":"10","author":"Genovese","year":"2019","journal-title":"Front Immunol"},{"issue":"2","key":"doi240039r7","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1590\/abd1806-4841.20199007","article-title":"Bullous pemphigoid.","volume":"94","author":"Miyamoto","year":"2019","journal-title":"An Bras Dermatol"},{"key":"doi240039r8","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.3389\/fimmu.2017.01752","article-title":"BP180 is critical in the autoimmunity of bullous pemphigoid.","volume":"8","author":"Liu","year":"2017","journal-title":"Front Immunol"},{"issue":"1","key":"doi240039r9","first-page":"4","article-title":"Introducing a novel Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) in pemphigus.","volume":"17","author":"Pf\u00fctze","year":"2007","journal-title":"Eur J Dermatol"},{"issue":"10","key":"doi240039r10","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1038\/jid.2009.72","article-title":"Reliability and convergent validity of two outcome instruments for pemphigus.","volume":"129","author":"Rosenbach","year":"2009","journal-title":"J Invest Dermatol"},{"issue":"3","key":"doi240039r11","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.jaad.2011.06.032","article-title":"Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts.","volume":"66","author":"Murrell","year":"2012","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"doi240039r12","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jdermsci.2004.10.007","article-title":"Correlation of clinical severity and ELISA indices for the NC16A domain of BP180 measured using BP180 ELISA kit in bullous pemphigoid.","volume":"37","author":"Tsuji-Abe","year":"2005","journal-title":"J Dermatol Sci"},{"issue":"3","key":"doi240039r13","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/S0923-1811(02)00109-3","article-title":"BP180 ELISA using bacterial recombinant NC16a protein as a diagnostic and monitoring tool for bullous pemphigoid.","volume":"30","author":"Kobayashi","year":"2002","journal-title":"J Dermatol Sci"},{"issue":"4","key":"doi240039r14","doi-asserted-by":"publisher","first-page":"204","DOI":"10.4103\/1027-8117.362992","article-title":"Ten essential steps for performing a systematic review: a quick tutorial.","volume":"40","author":"Kuo","year":"2022","journal-title":"Dermato"},{"issue":"15","key":"doi240039r15","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group.","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"issue":"10","key":"doi240039r16","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1111\/jdv.18220","article-title":"Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV).","volume":"36","author":"Borradori","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"8","key":"doi240039r17","doi-asserted-by":"publisher","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","article-title":"QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies.","volume":"155","author":"Whiting","year":"2011","journal-title":"Ann Intern Med"},{"issue":"4","key":"doi240039r20","doi-asserted-by":"publisher","first-page":"272","DOI":"10.12932\/AP-231118-0446","article-title":"Anti-BP180 and anti-BP230 enzyme-linked immunosorbent assays for diagnosis and disease activity tracking of bullous pemphigoid: a prospective cohort study.","volume":"39","author":"Chanprapaph","year":"2021","journal-title":"Asian Pac J Allergy Immunol"},{"issue":"3","key":"doi240039r21","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1001\/archdermatol.2011.23","article-title":"Usefulness of BP230 and BP180-NC16a enzyme-linked immunosorbent assays in the initial diagnosis of bullous pemphigoid: a retrospective study of 138 patients.","volume":"147","author":"Charneux","year":"2011","journal-title":"Arch Dermatol"},{"issue":"Nov","key":"doi240039r22","doi-asserted-by":"publisher","first-page":"2687","DOI":"10.3389\/fimmu.2018.02687","article-title":"Complement-activating capacity of autoantibodies correlates with disease activity in bullous pemphigoid patients.","volume":"9","author":"Chiorean","year":"2018","journal-title":"Front Immunol"},{"issue":"MAR","key":"doi240039r23","doi-asserted-by":"publisher","first-page":"479","DOI":"10.3389\/fimmu.2018.00479","article-title":"Mucosal involvement in bullous pemphigoid is mostly associated with disease severity and to absence of anti-BP230 autoantibody.","volume":"9","author":"Clap\u00e9","year":"2018","journal-title":"Front Immunol"},{"issue":"4","key":"doi240039r24","doi-asserted-by":"publisher","DOI":"10.1016\/j.xjidi.2021.100050","article-title":"Assessing disease outcome measures in bullous pemphigoid on standard-of-care therapies.","volume":"1","author":"Cole","year":"2021","journal-title":"JID Innov"},{"issue":"3","key":"doi240039r25","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s00403-018-1817-9","article-title":"BPDAI and ABSIS correlate with serum anti-BP180 NC16A IgG but not with anti-BP230 IgG in patients with bullous pemphigoid.","volume":"310","author":"Daneshpazhooh","year":"2018","journal-title":"Arch Dermatol Res"},{"issue":"2","key":"doi240039r26","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.jdermsci.2024.03.009","article-title":"Anti-BP230 IgE autoantibodies in bullous pemphigoid intraindividually correlate with disease activity.","volume":"114","author":"Emtenani","year":"2024","journal-title":"J Dermatol Sci"},{"issue":"2","key":"doi240039r27","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1159\/000362717","article-title":"Assessment of bullous pemphigoid disease area index during treatment: a prospective study of 30 patients.","volume":"229","author":"L\u00e9vy-Sitbon","year":"2014","journal-title":"Dermatology"},{"issue":"6","key":"doi240039r28","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1111\/bjd.19611","article-title":"International validation of the Bullous Pemphigoid Disease Area Index severity score and calculation of cut-off values for defining mild, moderate and severe types of bullous pemphigoid.","volume":"184","author":"Masmoudi","year":"2021","journal-title":"Br J Dermatol"},{"issue":"5","key":"doi240039r29","doi-asserted-by":"publisher","first-page":"696","DOI":"10.4103\/idoj.IDOJ_813_20","article-title":"A cross-sectional study to correlate disease severity in bullous pemphigoid patients with serum levels of autoantibodies against BP180 and BP230.","volume":"12","author":"Muhammed","year":"2021","journal-title":"Indian Dermatol Online J"},{"key":"doi240039r30","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/854795","article-title":"Association of autoantibodies to BP180 with disease activity in Greek patients with bullous pemphigoid.","volume":"2012","author":"Patsatsi","year":"2012","journal-title":"Clin Dev Immunol"},{"issue":"3","key":"doi240039r31","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1001\/archdermatol.2011.21","article-title":"Enzyme-linked immunosorbent assay for the combination of bullous pemphigoid antigens 1 and 2 in the diagnosis of bullous pemphigoid.","volume":"147","author":"Roussel","year":"2011","journal-title":"Arch Dermatol"},{"issue":"6","key":"doi240039r32","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1684\/ejd.2023.4573","article-title":"IgE anti-BP180 NC16A autoantibody in both serum and blister fluid samples does not correlate with disease activity of bullous pemphigoid.","volume":"33","author":"Sun","year":"2023","journal-title":"Eur J Dermatol"},{"issue":"1","key":"doi240039r33","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1001\/jamadermatol.2016.3357","article-title":"Correlation of serum levels of ige autoantibodies against BP180 with bullous pemphigoid disease activity.","volume":"153","author":"Van Beek","year":"2017","journal-title":"JAMA Dermatol"},{"issue":"1","key":"doi240039r34","doi-asserted-by":"publisher","first-page":"24","DOI":"10.2340\/00015555-2473","article-title":"The reliability, validity and responsiveness of two disease scores (BPDAI and ABSIS) for bullous pemphigoid: which one to use?","volume":"97","author":"Wijayanti","year":"2017","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"doi240039r35","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/j.1600-0625.1995.tb00062.x","article-title":"Bullous pemphigoid: serum antibody titer and antigen specificity.","volume":"4","author":"Pas","year":"1995","journal-title":"Exp Dermatol"},{"issue":"4","key":"doi240039r36","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/0190-9622(92)70085-T","article-title":"Lack of predictive factors for the clinical course of bullous pemphigoid.","volume":"26","author":"Venning","year":"1992","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"doi240039r37","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1001\/archderm.136.2.174","article-title":"Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid.","volume":"136","author":"Schmidt","year":"2000","journal-title":"Arch Dermatol"},{"issue":"1","key":"doi240039r38","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/j.1365-2133.1971.tb14190.x","article-title":"Correlation of pemphigoid and pemphigus antibody titres with activity of disease.","volume":"84","author":"Sams","year":"1971","journal-title":"Br J Dermatol"},{"issue":"5","key":"doi240039r39","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1001\/archdermatol.2009.53","article-title":"Risk factors for relapse in patients with bullous pemphigoid in clinical remission: a multicenter, prospective, cohort study.","volume":"145","author":"Bernard","year":"2009","journal-title":"Arch Dermatol"},{"issue":"8","key":"doi240039r40","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1016\/j.jid.2018.03.002","article-title":"High Expression of collagen XVII compensates for its depletion induced by pemphigoid IgG in the oral mucosa.","volume":"138","author":"Kamaguchi","year":"2018","journal-title":"J Invest Dermatol"},{"issue":"3","key":"doi240039r41","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1046\/j.1365-2230.1999.00457.x","article-title":"Bullous pemphigoid: correlation of mucosal involvement and mucosal expression of autoantigens studied by indirect immunofluorescence and immunoblotting.","volume":"24","author":"Kirtschig","year":"1999","journal-title":"Clin Exp Dermatol"},{"issue":"5","key":"doi240039r42","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1046\/j.1523-1747.2002.19529.x","article-title":"Severity and phenotype of bullous pemphigoid relate to autoantibody profile against the NH2- and COOH-terminal regions of the BP180 ectodomain.","volume":"119","author":"Hofmann","year":"2002","journal-title":"J Invest Dermatol"},{"issue":"12","key":"doi240039r43","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1111\/exd.13331","article-title":"Autoantibodies of non-inflammatory bullous pemphigoid hardly deplete type XVII collagen of keratinocytes.","volume":"26","author":"Imafuku","year":"2017","journal-title":"Exp Dermatol"},{"issue":"1-2","key":"doi240039r44","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jim.2009.04.013","article-title":"A novel ELISA reveals high frequencies of BP180-specific IgE production in bullous pemphigoid.","volume":"346","author":"Messingham","year":"2009","journal-title":"J Immunol Methods"},{"issue":"2","key":"doi240039r45","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jdermsci.2007.08.008","article-title":"Serum levels of IgE anti-BP180 and anti-BP230 autoantibodies in patients with bullous pemphigoid.","volume":"49","author":"Ishiura","year":"2008","journal-title":"J Dermatol Sci"},{"issue":"2","key":"doi240039r46","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/1346-8138.13051","article-title":"Serum levels of immunoglobulins G1 and G4 targeting the non-collagenous 16A domain of BP180 reflect bullous pemphigoid activity and predict bad prognosis.","volume":"43","author":"Zhou","year":"2016","journal-title":"J Dermatol"},{"issue":"4","key":"doi240039r47","doi-asserted-by":"publisher","first-page":"119","DOI":"10.47102\/annals-acadmedsg.V44N4p119","article-title":"Anti-BP180 NC16A IgG titres as an indicator of disease activity and outcome in Asian patients with bullous pemphigoid.","volume":"44","author":"Cai","year":"2015","journal-title":"Ann Acad Med Singap"},{"issue":"4","key":"doi240039r48","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1111\/bjd.16553","article-title":"Prospective study in bullous pemphigoid: association of high serum anti-BP180 IgG levels with increased mortality and reduced Karnofsky score.","volume":"179","author":"Holtsche","year":"2018","journal-title":"Br J Dermatol"},{"issue":"7","key":"doi240039r49","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1111\/jdv.16363","article-title":"Anti-BP180 autoantibody levels at diagnosis correlate with 1-year mortality rates in patients with bullous pemphigoid.","volume":"34","author":"Monshi","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"doi240039r50","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s12016-023-08973-1","article-title":"Advancing treatment in bullous pemphigoid: a comprehensive review of novel therapeutic targets and approaches.","volume":"65","author":"Chen","year":"2023","journal-title":"Clin Rev Allergy Immunol"},{"issue":"3","key":"doi240039r51","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jdermsci.2017.07.012","article-title":"IgG4, complement, and the mechanisms of blister formation in pemphigus and bullous pemphigoid.","volume":"88","author":"Dainichi","year":"2017","journal-title":"J Dermatol Sci"},{"key":"doi240039r52","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.973702","article-title":"The relevance of complement in pemphigoid diseases: A critical appraisal.","volume":"13","author":"Papara","year":"2022","journal-title":"Front Immunol"},{"issue":"1","key":"doi240039r53","doi-asserted-by":"publisher","first-page":"45","DOI":"10.5021\/ad.2012.24.1.45","article-title":"Usefulness of enzyme-linked immunosorbent assay using recombinant BP180 and BP230 for serodiagnosis and monitoring disease activity of bullous pemphigoid.","volume":"24","author":"Lee","year":"2012","journal-title":"Ann Dermatol"},{"issue":"3","key":"doi240039r54","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1111\/j.1365-4632.2008.03473.x","article-title":"Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid.","volume":"47","author":"Feng","year":"2008","journal-title":"Int J Dermatol"},{"key":"doi240039r55","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/j.1749-6632.2009.04630.x","article-title":"Evaluation of a new ELISA assay for detection of BP230 autoantibodies in bullous pemphigoid.","volume":"1173","author":"Tampoia","year":"2009","journal-title":"Ann N Y Acad Sci"},{"key":"doi240039r18","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/9780470743386.ch6","volume-title":"Introduction to Meta-Analysis","author":"Borenstein","year":"2009"},{"key":"doi240039r19","volume-title":"Statistics at Square One","author":"Swinscow","year":"2002"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2824268\/jamadermatology_chou_2024_oi_240039_1731688970.63894.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T11:01:56Z","timestamp":1732100516000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2824268"}},"subtitle":["A Systematic Review and Meta-Analysis"],"short-title":[],"issued":{"date-parts":[[2024,11,1]]},"references-count":55,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2024.3425","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,1]]}}}